Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))

A. Özkan; E. Kapiteijn; F. van den Bos; M. J.B. Aarts; F. W.P.J. van den Berkmortel; C. U. Blank; M. Bloem; W. A.M. Blokx; M. J. Boers-Sonderen; J. J. Bonenkamp; A. J.M. van den Eertwegh; J. W.B. de Groot; J. B. Haanen; C. E. Holtslag; G. A.P. Hospers; D. Piersma; R. S. van Rijn; A. M. Stevense-den Boer; K. P.M. Suijkerbuijk; A. A.M. van der Veldt; G. Vreugdenhil; M. W.J.M. Wouters; J. E.A. Portielje; N. A. de Glas

doi:10.1016/j.ejca.2024.115194

Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))

A. Özkan
, E. Kapiteijn
, F. van den Bos
, M. J.B. Aarts
, F. W.P.J. van den Berkmortel
, C. U. Blank
, M. Bloem
, W. A.M. Blokx
, M. J. Boers-Sonderen
, J. J. Bonenkamp
, A. J.M. van den Eertwegh
, J. W.B. de Groot
, J. B. Haanen
, C. E. Holtslag
, G. A.P. Hospers
, D. Piersma
, R. S. van Rijn
, A. M. Stevense-den Boer
, K. P.M. Suijkerbuijk
, A. A.M. van der Veldt

G. Vreugdenhil, M. W.J.M. Wouters, J. E.A. Portielje, N. A. de Glas^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum › Academic

Abstract

The authors regret an error in Figure S3 of this manuscript. The Kaplan-Meier plot does not start at 100 %, as it should. This style has now been amended in all supplementary figures [Figure presented] Figure S3.Recurrence-free survival in older melanoma patients (≥65)treated with adjuvant anti-PD-1 therapy by comorbidity categories.Recurrence-free survivalof patients with 1–2 comorbidities vs. 0 comorbidities p = 0.542, (HR 1.15 95 %, CI: 0.73–1.83). Patients with 3 or more comorbidities vs. 0 comorbidities p < 0.001 (HR of 2.76, 95 % CI: 1.79–4.26). One patient was not included in this analysis due to missing data necessary for calculating RFS. We kindly request that the other figures (S2, S4, S5) be updated to align with this new style, which we believe represents a significant improvement. The table displaying numbers at risk is now better aligned with the figure, and we have replaced symbols with traditional Kaplan-Meier lines to enhance clarity. [Figure presented] Figure S2. Kaplan–Meier estimate of recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy. One patient was not included in this analysis due to missing data necessary for calculating RFS. [Figure presented] Figure S4. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by ECOG Performance Status categories. HR: 3.78, 95 %C.I. 1.16–12.39, p = 0.028. 38 patients were not included in this analysis due to missing data necessary for calculating RFS. [Figure presented]Figure S5. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by tumor stage (AJCC 8 ^th edition). The RFS was compared across all stages relative to stage IIIA. Only stage IIIC showed a significantly decreased RFS (HR: 1.66, 95 %C.I. 1.66–2.48, p = 0.014). One patient was not included in this analysis due to missing data necessary for calculating RFS. The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	115194
Number of pages	4
Journal	European Journal of Cancer
Volume	216
DOIs	https://doi.org/10.1016/j.ejca.2024.115194
Publication status	Published - 5 Feb 2025

Access to Document

10.1016/j.ejca.2024.115194

Fingerprint

Dive into the research topics of 'Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))'. Together they form a unique fingerprint.

1 Article

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Bloem, M., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B., Holtslag, C. E., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Stevense-den Boer, A. M., Suijkerbuijk, K. P. M. & van der Veldt, A. A. M. & 4 others, Vreugdenhil, G., Wouters, M. W. J. M., Portielje, J. E. A. & de Glas, N. A., 1 Nov 2024, In: European Journal of Cancer. 212, 8 p., 115056.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Bloem, M., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B., Holtslag, C. E., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Stevense-den Boer, A. M., Suijkerbuijk, K. P. M., ... de Glas, N. A. (2025). Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056)). European Journal of Cancer, 216, Article 115194. https://doi.org/10.1016/j.ejca.2024.115194

Özkan, A. ; Kapiteijn, E. ; van den Bos, F. et al. / Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma : Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056)). In: European Journal of Cancer. 2025 ; Vol. 216.

@article{4bb0b6e3fbaf4269a3f735c2039b1c00,

title = "Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))",

abstract = "The authors regret an error in Figure S3 of this manuscript. The Kaplan-Meier plot does not start at 100 \%, as it should. This style has now been amended in all supplementary figures [Figure presented] Figure S3.Recurrence-free survival in older melanoma patients (≥65)treated with adjuvant anti-PD-1 therapy by comorbidity categories.Recurrence-free survivalof patients with 1–2 comorbidities vs. 0 comorbidities p = 0.542, (HR 1.15 95 \%, CI: 0.73–1.83). Patients with 3 or more comorbidities vs. 0 comorbidities p < 0.001 (HR of 2.76, 95 \% CI: 1.79–4.26). One patient was not included in this analysis due to missing data necessary for calculating RFS. We kindly request that the other figures (S2, S4, S5) be updated to align with this new style, which we believe represents a significant improvement. The table displaying numbers at risk is now better aligned with the figure, and we have replaced symbols with traditional Kaplan-Meier lines to enhance clarity. [Figure presented] Figure S2. Kaplan–Meier estimate of recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy. One patient was not included in this analysis due to missing data necessary for calculating RFS. [Figure presented] Figure S4. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by ECOG Performance Status categories. HR: 3.78, 95 \%C.I. 1.16–12.39, p = 0.028. 38 patients were not included in this analysis due to missing data necessary for calculating RFS. [Figure presented]Figure S5. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by tumor stage (AJCC 8 th edition). The RFS was compared across all stages relative to stage IIIA. Only stage IIIC showed a significantly decreased RFS (HR: 1.66, 95 \%C.I. 1.66–2.48, p = 0.014). One patient was not included in this analysis due to missing data necessary for calculating RFS. The authors would like to apologise for any inconvenience caused.",

author = "A. {\"O}zkan and E. Kapiteijn and \{van den Bos\}, F. and Aarts, \{M. J.B.\} and \{van den Berkmortel\}, \{F. W.P.J.\} and Blank, \{C. U.\} and M. Bloem and Blokx, \{W. A.M.\} and Boers-Sonderen, \{M. J.\} and Bonenkamp, \{J. J.\} and \{van den Eertwegh\}, \{A. J.M.\} and \{de Groot\}, \{J. W.B.\} and Haanen, \{J. B.\} and Holtslag, \{C. E.\} and Hospers, \{G. A.P.\} and D. Piersma and \{van Rijn\}, \{R. S.\} and \{Stevense-den Boer\}, \{A. M.\} and Suijkerbuijk, \{K. P.M.\} and \{van der Veldt\}, \{A. A.M.\} and G. Vreugdenhil and Wouters, \{M. W.J.M.\} and Portielje, \{J. E.A.\} and \{de Glas\}, \{N. A.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2025",

month = feb,

day = "5",

doi = "10.1016/j.ejca.2024.115194",

language = "English",

volume = "216",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Özkan, A, Kapiteijn, E, van den Bos, F, Aarts, MJB, van den Berkmortel, FWPJ, Blank, CU, Bloem, M, Blokx, WAM, Boers-Sonderen, MJ, Bonenkamp, JJ, van den Eertwegh, AJM, de Groot, JWB, Haanen, JB, Holtslag, CE, Hospers, GAP, Piersma, D, van Rijn, RS, Stevense-den Boer, AM, Suijkerbuijk, KPM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Portielje, JEA & de Glas, NA 2025, 'Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))', European Journal of Cancer, vol. 216, 115194. https://doi.org/10.1016/j.ejca.2024.115194

Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056)). / Özkan, A.; Kapiteijn, E.; van den Bos, F. et al.
In: European Journal of Cancer, Vol. 216, 115194, 05.02.2025.

Research output: Contribution to journal › Erratum / corrigendum › Academic

TY - JOUR

T1 - Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma

T2 - Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056))

AU - Özkan, A.

AU - Kapiteijn, E.

AU - van den Bos, F.

AU - Aarts, M. J.B.

AU - van den Berkmortel, F. W.P.J.

AU - Blank, C. U.

AU - Bloem, M.

AU - Blokx, W. A.M.

AU - Boers-Sonderen, M. J.

AU - Bonenkamp, J. J.

AU - van den Eertwegh, A. J.M.

AU - de Groot, J. W.B.

AU - Haanen, J. B.

AU - Holtslag, C. E.

AU - Hospers, G. A.P.

AU - Piersma, D.

AU - van Rijn, R. S.

AU - Stevense-den Boer, A. M.

AU - Suijkerbuijk, K. P.M.

AU - van der Veldt, A. A.M.

AU - Vreugdenhil, G.

AU - Wouters, M. W.J.M.

AU - Portielje, J. E.A.

AU - de Glas, N. A.

PY - 2025/2/5

Y1 - 2025/2/5

N2 - The authors regret an error in Figure S3 of this manuscript. The Kaplan-Meier plot does not start at 100 %, as it should. This style has now been amended in all supplementary figures [Figure presented] Figure S3.Recurrence-free survival in older melanoma patients (≥65)treated with adjuvant anti-PD-1 therapy by comorbidity categories.Recurrence-free survivalof patients with 1–2 comorbidities vs. 0 comorbidities p = 0.542, (HR 1.15 95 %, CI: 0.73–1.83). Patients with 3 or more comorbidities vs. 0 comorbidities p < 0.001 (HR of 2.76, 95 % CI: 1.79–4.26). One patient was not included in this analysis due to missing data necessary for calculating RFS. We kindly request that the other figures (S2, S4, S5) be updated to align with this new style, which we believe represents a significant improvement. The table displaying numbers at risk is now better aligned with the figure, and we have replaced symbols with traditional Kaplan-Meier lines to enhance clarity. [Figure presented] Figure S2. Kaplan–Meier estimate of recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy. One patient was not included in this analysis due to missing data necessary for calculating RFS. [Figure presented] Figure S4. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by ECOG Performance Status categories. HR: 3.78, 95 %C.I. 1.16–12.39, p = 0.028. 38 patients were not included in this analysis due to missing data necessary for calculating RFS. [Figure presented]Figure S5. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by tumor stage (AJCC 8 th edition). The RFS was compared across all stages relative to stage IIIA. Only stage IIIC showed a significantly decreased RFS (HR: 1.66, 95 %C.I. 1.66–2.48, p = 0.014). One patient was not included in this analysis due to missing data necessary for calculating RFS. The authors would like to apologise for any inconvenience caused.

AB - The authors regret an error in Figure S3 of this manuscript. The Kaplan-Meier plot does not start at 100 %, as it should. This style has now been amended in all supplementary figures [Figure presented] Figure S3.Recurrence-free survival in older melanoma patients (≥65)treated with adjuvant anti-PD-1 therapy by comorbidity categories.Recurrence-free survivalof patients with 1–2 comorbidities vs. 0 comorbidities p = 0.542, (HR 1.15 95 %, CI: 0.73–1.83). Patients with 3 or more comorbidities vs. 0 comorbidities p < 0.001 (HR of 2.76, 95 % CI: 1.79–4.26). One patient was not included in this analysis due to missing data necessary for calculating RFS. We kindly request that the other figures (S2, S4, S5) be updated to align with this new style, which we believe represents a significant improvement. The table displaying numbers at risk is now better aligned with the figure, and we have replaced symbols with traditional Kaplan-Meier lines to enhance clarity. [Figure presented] Figure S2. Kaplan–Meier estimate of recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy. One patient was not included in this analysis due to missing data necessary for calculating RFS. [Figure presented] Figure S4. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by ECOG Performance Status categories. HR: 3.78, 95 %C.I. 1.16–12.39, p = 0.028. 38 patients were not included in this analysis due to missing data necessary for calculating RFS. [Figure presented]Figure S5. Recurrence-free survival in older melanoma patients (≥65) treated with adjuvant anti-PD-1 therapy by tumor stage (AJCC 8 th edition). The RFS was compared across all stages relative to stage IIIA. Only stage IIIC showed a significantly decreased RFS (HR: 1.66, 95 %C.I. 1.66–2.48, p = 0.014). One patient was not included in this analysis due to missing data necessary for calculating RFS. The authors would like to apologise for any inconvenience caused.

U2 - 10.1016/j.ejca.2024.115194

DO - 10.1016/j.ejca.2024.115194

M3 - Erratum / corrigendum

SN - 0959-8049

VL - 216

JO - European Journal of Cancer

JF - European Journal of Cancer

M1 - 115194

ER -

Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU et al. Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056)). European Journal of Cancer. 2025 Feb 5;216:115194. doi: 10.1016/j.ejca.2024.115194